Abstract
Novel therapeutic approaches targeting signaling pathways involved in cell proliferation, apoptosis, angiogenesis and metastasis have been under clinical development. Of many potential targets in adult solid tumors, the epidermal growth factor receptor (EGFR) has been the most extensively studied since its over-expression has been observed in several common solid tumors. However, the insurgence for resistance to drugs targeting the EGF-receptor has been described. The understanding of the mechanisms which are responsible of resistance to EGFR inhibitors could lead to the development of improved strategies to integrate anti-EGFR therapies. In this review, we will describe the latest new strategies developed to optimize the therapeutic effects of EGFR inhibitors, by exploring combinations with other molecular targeted approaches including other erbB family member inhibitors, drugs with different structure and mechanism of action, other tumor cell-directed signal transduction inhibitors, anti-angiogenic treatment modalities, and the use of broad spectrum EGFR tyrosine kinase inhibitors.
Keywords: EGFR, angiogenesis, combination treatment, targeted therapy
Current Cancer Therapy Reviews
Title: Combination of Anti-EGFR Drugs and Other Molecular Targeted Agents as Anti-Cancer Strategy
Volume: 3 Issue: 2
Author(s): Floriana Morgillo, Erika Martinelli, Teresa Troiani, Giampaolo Tortora and Fortunato Ciardiello
Affiliation:
Keywords: EGFR, angiogenesis, combination treatment, targeted therapy
Abstract: Novel therapeutic approaches targeting signaling pathways involved in cell proliferation, apoptosis, angiogenesis and metastasis have been under clinical development. Of many potential targets in adult solid tumors, the epidermal growth factor receptor (EGFR) has been the most extensively studied since its over-expression has been observed in several common solid tumors. However, the insurgence for resistance to drugs targeting the EGF-receptor has been described. The understanding of the mechanisms which are responsible of resistance to EGFR inhibitors could lead to the development of improved strategies to integrate anti-EGFR therapies. In this review, we will describe the latest new strategies developed to optimize the therapeutic effects of EGFR inhibitors, by exploring combinations with other molecular targeted approaches including other erbB family member inhibitors, drugs with different structure and mechanism of action, other tumor cell-directed signal transduction inhibitors, anti-angiogenic treatment modalities, and the use of broad spectrum EGFR tyrosine kinase inhibitors.
Export Options
About this article
Cite this article as:
Morgillo Floriana, Martinelli Erika, Troiani Teresa, Tortora Giampaolo and Ciardiello Fortunato, Combination of Anti-EGFR Drugs and Other Molecular Targeted Agents as Anti-Cancer Strategy, Current Cancer Therapy Reviews 2007; 3 (2) . https://dx.doi.org/10.2174/157339407780618434
DOI https://dx.doi.org/10.2174/157339407780618434 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mechanisms and Inhibitors of Apoptosis in Cardiovascular Diseases
Current Pharmaceutical Design Quinazolines as Apoptosis Inducers and Inhibitors: A Review of Patent Literature
Recent Patents on Anti-Cancer Drug Discovery Inhibition of Autophagy Strengthens Celastrol-Induced Apoptosis in Human Pancreatic Cancer In Vitro and In Vivo Models
Current Molecular Medicine Recent Software Developments and Applications in Functional Imaging
Current Pharmaceutical Biotechnology Intravenous and Regional Paclitaxel Formulations
Current Medicinal Chemistry Potential Therapeutic Effects of Na+/Ca2+ Exchanger Inhibition in Cardiac Diseases
Current Medicinal Chemistry IL-2 Receptor Targeted Immunomodulatory Biologics: The Past, Present, and Future
Current Immunology Reviews (Discontinued) Strategies for Targeting Lentiviral Vectors
Current Gene Therapy Stem Cell-Mediated Delivery of Therapies in the Treatment of Glioma
Mini-Reviews in Medicinal Chemistry Editorial (Thematic Issue: “Alkaloids in Nature: Synthesis, Isolation and Pharmacological Applications” Part 2)
Current Topics in Medicinal Chemistry Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) Mitochondrial Superoxide Dismutase - Signals of Distinction
Anti-Cancer Agents in Medicinal Chemistry Endothelial Colony Forming Capacity is Related to C-Reactive Protein Levels in Healthy Subjects
Current Neurovascular Research <i>In vivo</i> Anticancer Potential of Hydroxamic Acid Derivatives
Current Topics in Medicinal Chemistry Advances in Helper-Dependent Adenoviral Vector Research
Current Gene Therapy Protein Pool Maintenance During Oxidative Stress
Current Pharmaceutical Design Aptamers as Targeting Delivery Devices or Anti-cancer Drugs for Fighting Tumors
Current Drug Metabolism Production of β -cyclodextrin from pH and Thermo Stable Cyclodextrin Glycosyl Transferase, Obtained from Arthrobacter mysorens and Its Evaluation as a Drug Carrier for Irbesartan
Current Drug Delivery Prospects of Non-Coding Elements in Genomic DNA Based Gene Therapy
Current Gene Therapy The Tumor Suppressor Gene ARF as a Sensor of Oxidative Stress
Current Molecular Medicine